Incidence, Epidemiology and Patterns of Progression of Prostate Cancer
Article information
J Korean Med Assoc. 2010;53(2):92-97
Publication date (electronic) : 2010 February 28
doi :
https://doi.org/10.5124/jkma.2010.53.2.92
Abstract
Prostate cancer is the fourth most common cancer in men worldwide. Its incidence and mortality vary widely between countries and ethnicities. In Korea, the incidence of prostate cancer was much lower than that in most westernized countries, but recently, it appears to be rapidly increasing steadily. Prostate cancer has now become the fifth most common cancer in men in Korea since the year 2002. The recent dramatic increase in incidence may be attributed to the growth of elderly population, a westernized diet in daily life style, and introduction of prostate-specific antigen (PSA) screening. The prevalence of latent prostate cancers is similar around the world, but the incidence of clinically manifest cancers differs, with Asians having the lowest rates of clinical prostate cancers. Diet may play a role in converting latent prostate cancer into clinically manifest one. Fat consumption, especially polyunsaturated fat, shows a strong positive correlation with prostate cancer incidence and mortality. The mortality rates for prostate cancer have been decreasing in many developed countries, thanks to early detection and improved treatment, while the mortality rates have been increasing in Korea. Since a significantly higher proportion of Korean prostate cancers exhibit poor differentiation, early diagnosis and appropriate treatment may be important.
Keywords: Prostate cancer; Incidence; Mortality; Progression
References
1. Klein EA, Platz EA, Thompson IM. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Epidemiology, etiology, and prevention of prostate cancer. Campbell-Walsh urology 2007. 9th edth ed. Philadelphia: Saunders; 2854–2873.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009. 59225–249.
3. Korea Central Cancer Registry, National Cancer Center. Cancer Statistics in Korea
http://www.ncc.re.kr.
4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG, Ahn YO, Lee SY, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM. Nationwide cancer incidence in Korea, 1999-2001; first result using the national cancer incidence database. Cancer Res Treat 2005. 37325–331.
5. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, Seo SW, Kim KY, Lee SY, Kong IS, Hwang IK, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM, Yoo KY. National cancer incidence for the year 2002 in Korea. Cancer Res Treat 2007. 39139. 149.
6. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009. 41122–131.
7. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, Ahn YO, Shin MH, Lee CW, Lee DH, Blair A, Devesa SS, Hsing AW. Rising prostate cancer rates in South Korea. Prostate 2006. 661285–1291.
8. The Korean Urological Association. Data on statistics of management in resident training hospital in the Korean Urological Association: 1984-2002 2004. Seoul: Eui-hak Publishing & Printing Co.; 18–19.
9. The Korean Urological Association. Data on statistics of management in resident training hospital in the Korean Urological Association in the year 2007. Korean J Urol 2008. 491171–1172.
10. Sata F, Umemura T, Kishi R. The epidemiology of prostate cancer-recent trends in prostate cancer incidence and mortality. Gan To Kagaku Ryoho 2001. 28184–188.
11. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995. 273548–552.
12. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999. 911017–1024.
13. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003. 2891414–1420.
14. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009. 73S 5A. 4–10.
15. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008. 179892–895.
16. Presti JC Jr, Kane CJ, Shinohara K, Carroll PR. In : Tanagho EA, McAninch JW, eds. Neoplasms of the prostate gland. Smith's general urology 2008. 17th edth ed. New York: McGraw-Hill; 348–374.
17. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004. 10110 S. 2371–2490.
18. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990. 143742–746.
19. Hsing AW, Sakoda LC, Chua SC Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007. 86S. 843S–857S.
20. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001. 233–13.
21. Kim SC. A continuous increase in prevalence of prostate cancer in Korea and its causes. J Korean Med Assoc 2004. 47394–402.
22. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982. 127928–934.
23. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Shanberg AM, Toi A. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996. 77150–159.
24. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002. 60756–759.
25. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, Reuther AM, Klein EA. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004. 22300–306.
26. Song K, Song C, Ahn H. Continuing trends of the clinical parameter migration in patients with prostate cancer in Korea. Korean J Urol 2007. 48574–578.
27. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, Shin HR. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci 2007. 22S. S5–S10.
28. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000. 2832975–2978.
29. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003. 30219–226.
30. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003. 1702444–2452.
31. Barnes RW. Survival with conservative therapy. JAMA 1969. 210331–332.
32. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974. 11158–64.
33. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994. 330242–248.
34. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2004. 2912713–2719.
35. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010. 28126–131.
36. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999. 2811591–1597.
37. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR. CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database? J Urol 2008. 1801330–1334.
38. Song C, Kang T, Lee MS, Ro JY, Lee SE, Lee E, Choi HY, Han DH, Hong SJ, Chung BH, Kim CS, Ahn H. Clinico-pathological characteristics of prostate cancer in Korean men and nomograms for the prediction of the pathological stage of the clinically localized prostate cancer: a multi-institutional update. Korean J Urol 2007. 48125–130.
39. Song SY, Kim SR, Ahn G, Choi HY. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 2003. 6143–147.
Article information Continued
Copyright © 2010 Korean Medical Association